News Express: UM, Sinopharm establish collaboration in biomedical sciences
新聞快訊：澳大與國藥集團開展生物醫藥合作
簽約儀式
The agreement signing ceremony
澳大與國藥集團開展生物醫藥合作
中國醫藥集團有限公司董事長劉敬楨率代表團訪問澳門大學，獲澳大校長宋永華、副校長徐建等熱情接待。期間，雙方簽署戰略合作協議，開展生物醫藥相關合作。
宋永華向代表團介紹了澳大的優勢和未來發展規劃，並表示澳大一直高度重視健康科學領域教育和研發事業發展，不斷強化學科建設，積極配合國家發展戰略，不斷提升對生物醫藥大健康產業發展的支持力度。
其後，澳大與國藥集團共同簽署戰略合作協議，標誌著雙方將基於優勢互補、互惠互利、務求實效、共同發展的原則，建立戰略合作關係。雙方將在共建聯合實驗室、合作開展轉化研究、加強科技人才培養等方面開展深入合作。
代表團亦參觀了澳大中藥質量研究國家重點實驗室及健康科學學院實驗室，並舉行交流座談會。會上，雙方代表介紹了各自情況和合作優勢，並對下一步合作細節進行深入探討。雙方期望通過合作，在融合互促方面更好地發揮示範引領效應，助力提升澳琴生物醫藥大健康戰略科技力量。
國藥集團是由國務院國資委直接管理、以生命健康為主業的中央企業，全面服務“健康中國”戰略，集團規模、效益和綜合實力居於全球同行業領先地位。
代表團成員還包括國藥集團黨委委員、副總經理（主持日常經營工作）胡建偉，國藥集團黨委委員、副總經理董增賀，國藥集團副總經理晉斌，國藥集團首席科學家、國藥中生副總裁張雲濤，中國國際醫藥衛生有限公司黨委書記、董事長周頌，中國中藥控股有限公司黨委書記、董事長陳映龍，上海現代製藥股份有限公司副總裁倪峰，太極集團有限公司黨委書記、董事長俞敏，中國中藥控股有限公司副總裁蘭青山等國藥集團單位代表。
欲瀏覽官網版可登入以下連結:
https://www.um.edu.mo/zh-hant/news-and-press-releases/campus-news/detail/57790/
UM, Sinopharm establish collaboration in biomedical sciences
A delegation led by Liu Jingzhen, chairman of China National Pharmaceutical Group Co Ltd (Sinopharm), visited the University of Macau (UM) and was warmly received by UM Rector Yonghua Song and Vice Rector Xu Jian. During the visit, the two parties signed a strategic cooperation agreement to establish collaboration in biomedical sciences.
Song introduced to the delegation UM’s strengths and future development plans. He said that UM attaches great importance to the development of education and research in the field of health sciences and continuously enhances its academic offerings to support national development strategies and step up its support for the development of the biomedical and healthcare industry.
In addition, UM and Sinopharm signed a strategic cooperation agreement, which marks the establishment of a strategic partnership between the two parties based on the principles of complementarity, mutual benefit, pragmatism, and common development. Both parties will engage in in-depth cooperation in various aspects, including establishing joint laboratories, conducting joint translational research, and enhancing the cultivation of technology talent.
The Sinopharm delegation visited the State Key Laboratory of Quality Research in Chinese Medicine and the laboratories of the Faculty of Health Sciences, followed by a meeting. During the meeting, representatives from both sides gave an overview of their respective situations and advantages in cooperation and discussed in depth the details of future cooperation. Both parties hope that their cooperation will play a leading role in integration and mutual promotion, thereby boosting the strategic technological capabilities of Macao and Hengqin in the field of biomedical sciences and healthcare.
Sinopharm is a state-owned enterprise directly managed by the State-owned Assets Supervision and Administration Commission of the State Council. It is mainly engaged in the life and health sector and serves the Healthy China strategy. The group holds a leading position globally in terms of scale, profitability, and comprehensive strength within the industry.
Members of the Sinopharm delegation also included Hu Jianwei, party committee member and deputy general manager (daily operations) of Sinopharm; Dong Zenghe, party committee member and deputy general manager of Sinopharm; Jin Bin, deputy general manager of Sinopharm; Zhang Yuntao, chief scientist of Sinopharm and vice president of China National Biotec Group Co Ltd; Zhou Song, party committee secretary and chairman of China Sinopharm International Corporation; Chen Yinglong, party committee secretary and chairman of China Traditional Chinese Medicine Holdings Co Ltd; Ni Feng, vice president of Shanghai Shyndec Pharmaceutical Co Ltd; Yu Min, party committee secretary and chairman of Chongqing Taiji Industry Group Co Ltd; and Lan Qingshan, vice president of China Traditional Chinese Medicine Holdings Co Ltd.
To read the news on UM’s official website, please visit the following link:
https://www.um.edu.mo/news-and-press-releases/campus-news/detail/57790/